Recent Press Releases

Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder

09/21/16 - GERMANTOWN, Md., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced th... More

Neuralstem Presented NSI-189 Preclinical Data in Type 1 and Type 2 Diabetes at the Annual Meeting of the Diabetic Neuropathy Study Group

09/12/16 - NSI-189 Shows Prevention and Reversal of Diabetic Neuropathies in Mice GERMANTOWN, Md., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous... More

Neuralstem Receives $20,000,000 Strategic Investment from Tianjin Pharmaceutical Group

09/12/16 - GERMANTOWN, Md., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announ... More
More

Upcoming Events


There are currently no events scheduled.
More
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
Share PageShare Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts
Financial Tear SheetFinancial Tear Sheet